Abstract
Colorectal Cancer (CRC) is one of the most common cancers with a high rate of morbidity and mortality worldwide. It has been demonstrated that epigenetic alterations which may cause changes in the expression of microRNA, DNA methylation and histone acetylation that results in inheritable modifications in gene expression in colorectal epithelial cells, plays a crucial role in the development of CRC. Recently, targeting epigenetic modification has emerged as a potentially important treatment approach in CRC. The US Food and Drug Association has approved the use of some epigenetic drugs that may be able to inhibit or reverse these alterations and also enhance sensitivity to chemotherapeutic agents and radiotherapy in CRC. In this review we have summarized the recent pre-clinical and clinical trial studies investigating the therapeutic value of using epigenetic drugs as novel therapeutic approach in CRC treatment.
Keywords: Epigenetic, colorectal cancer, drug, DNA methylation, microRNA, histone acetylation, chemotherapeutic agents.
Current Pharmaceutical Design
Title:Epigenetic Drug Therapy in the Treatment of Colorectal Cancer
Volume: 24 Issue: 23
Author(s): Seyed Mostafa Parizadeh, Reza Jafarzadeh-Esfehani, Maryam Ghandehari, Sima Seifi, Seyed Mohammad Reza Parizadeh, Mehrdad Moetamani-Ahmadi, Seyed Mahdi Hassanian, Majid Khazaei, Majid Ghayour-Mobarhan, Gordon A. Ferns and Amir Avan*
Affiliation:
- Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: Epigenetic, colorectal cancer, drug, DNA methylation, microRNA, histone acetylation, chemotherapeutic agents.
Abstract: Colorectal Cancer (CRC) is one of the most common cancers with a high rate of morbidity and mortality worldwide. It has been demonstrated that epigenetic alterations which may cause changes in the expression of microRNA, DNA methylation and histone acetylation that results in inheritable modifications in gene expression in colorectal epithelial cells, plays a crucial role in the development of CRC. Recently, targeting epigenetic modification has emerged as a potentially important treatment approach in CRC. The US Food and Drug Association has approved the use of some epigenetic drugs that may be able to inhibit or reverse these alterations and also enhance sensitivity to chemotherapeutic agents and radiotherapy in CRC. In this review we have summarized the recent pre-clinical and clinical trial studies investigating the therapeutic value of using epigenetic drugs as novel therapeutic approach in CRC treatment.
Export Options
About this article
Cite this article as:
Parizadeh Mostafa Seyed , Jafarzadeh-Esfehani Reza , Ghandehari Maryam , Seifi Sima, Parizadeh Mohammad Reza Seyed , Moetamani-Ahmadi Mehrdad , Hassanian Mahdi Seyed , Khazaei Majid , Ghayour-Mobarhan Majid , Ferns A. Gordon and Avan Amir *, Epigenetic Drug Therapy in the Treatment of Colorectal Cancer, Current Pharmaceutical Design 2018; 24 (23) . https://dx.doi.org/10.2174/1381612824666180730151904
DOI https://dx.doi.org/10.2174/1381612824666180730151904 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Biochemical and Pharmacological Applications of Essential Oils in Human Health Especially in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Editorial
Current Drug Therapy Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective
Combinatorial Chemistry & High Throughput Screening Subcellular Accumulation and Modification of Pharmaceutical Proteins in Different Plant Tissues
Current Pharmaceutical Design The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science On the Power of Additional and Complex Chromosomal Aberrations in CML
Current Genomics Template Dependent Human DNA Polymerases
Current Topics in Medicinal Chemistry Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Netrin and DCC: Axon Guidance Regulators at the Intersection of Nervous System Development and Cancer
Current Drug Targets Tyrosine Kinase Mutations in Human Cancer
Current Molecular Medicine Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues
Current Drug Metabolism Chemical Analysis of the Chinese Herbal Medicine Turmeric (Curcuma longa L.)
Current Pharmaceutical Analysis Strategies for Salt Reduction in Foods
Recent Patents on Food, Nutrition & Agriculture From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Effects of Motivational Interview on Awareness, Attitude, and Practice of Breast Self-examination in High-risk Women: A Clinical Trial Study
Current Women`s Health Reviews Comparison of the Inhibitory Effects of Clotrimazole and Ketoconazole against Human Carboxylesterase 2
Current Drug Metabolism